Recommended Free Tools
GRO Biosciences (GRObio) announced on July 19, 2024, that it had closed an oversubscribed $60.3 million Series B financing, rounded to $60 million in the headline. Atlas Venture and Access Biotechnology co-led the round, which is intended to move the company’s lead gout program, ProGly-Uricase, toward clinical development while expanding its protein-engineering platform.
The financing is significant as a transition from preclinical platform work toward human testing—not as evidence that ProGly-Uricase has already demonstrated safety or efficacy in patients.
| # | Preview | Product | Price | |
|---|---|---|---|---|
| 1 |
|
Biotechnology | $105.68 | Buy on Amazon |
| 2 |
|
Basic Laboratory Methods for Biotechnology: Textbook and Laboratory Reference | $95.33 | Buy on Amazon |
| 3 |
|
Introduction to Biotechnology, Global Edition | $68.48 | Buy on Amazon |
| 4 |
|
Biotechnology: The Technological Applications of Genetics and Genomics | $148.42 | Buy on Amazon |
| 5 |
|
Introduction to Biotechnology (What's New in Biology) | $243.47 | Buy on Amazon |
Financing at a glance
| Item | Details |
|---|---|
| Announcement | July 19, 2024 |
| Round | Oversubscribed Series B |
| Amount | $60.3 million; $60 million in the headline |
| Co-leads | Atlas Venture and Access Biotechnology |
| Existing participants | Leaps by Bayer, Redmile Group, Digitalis Ventures and Innovation Endeavors |
| Total capital raised | More than $90 million after the round |
| Board appointments | Kevin Bitterman, PhD, and Dan Becker, MD, PhD |
| Headquarters | Cambridge, Massachusetts |
| Stated use of proceeds | Advance ProGly-Uricase toward clinical development, expand the pipeline and develop the GRO platform |
These details come from the company’s financing announcement: GRO Biosciences’ Series B announcement.
Why the lead program targets severe gout
Uricase enzymes break down uric acid and are used for patients with difficult-to-treat gout. In severe or refractory disease, urate can remain persistently high, driving painful inflammation and crystal deposits.
#1 Best Overall
A major limitation of uricase therapy is immunogenicity. Some patients develop anti-drug antibodies that clear the enzyme more quickly or reduce its activity. Treatment may then become less durable, leaving clinicians with a difficult balance between controlling uric acid and managing an immune response.
GRObio’s development hypothesis is that reducing this immune recognition could keep a uricase therapeutic in circulation longer and preserve its effect. That is a hypothesis to be tested clinically, not an established outcome.
How ProGly-Uricase is supposed to work
Proteins are built from amino acids. Human biology normally uses a canonical set of 20, but GRObio’s ProGly approach adds non-standard amino acids—chemical building blocks outside that usual biological alphabet.
The company says its ProGly amino acids carry glycans, or sugar structures, intended to alter how the immune system recognizes the therapeutic protein. For ProGly-Uricase, the goal is to reduce formation of anti-drug antibodies against the enzyme.
PC Slower Than It Used to Be?
A free scan shows the junk files, broken settings and background clutter dragging Windows down - then fixes them in one click.Free scan · Windows 10 & 11Crashes, No Sound, or Screen Glitches?
Random freezes, missing sound and display glitches usually trace back to one bad driver. Find and replace yours safely.Free scan · under a minute- Biochemical activity: whether the engineered enzyme still breaks down uric acid.
- Immunogenicity: whether patients make antibodies against it.
- Exposure: how long active drug remains in circulation.
- Clinical benefit: whether serum uric acid, flares or tophi improve for patients.
- Regulatory success: whether evidence ultimately supports approval.
Success at one level would not automatically establish success at the next. The financing announcement described the rationale and preclinical progress; it did not report human efficacy or durability data.
What the GRO platform adds
A genomically recoded organism is an engineered production organism whose genetic code has been altered so that selected codons can be reassigned to non-standard amino acids. In principle, this lets a cell manufacture proteins with chemical features that conventional recombinant systems cannot easily provide.
GRObio says its GRO platform is designed to incorporate multiple non-standard amino acids into therapeutic proteins and to support combinations intended to influence immune recognition, tissue targeting or drug function. The company also describes the platform as scalable, but that is a company claim that still requires pharmaceutical-scale manufacturing validation.
The platform’s value therefore depends on two separate achievements: reliably making each candidate with the intended chemistry, and showing that the engineered chemistry produces a meaningful clinical advantage.
Free tools Windows power users keep installed
One-click scans. No signup required.
Rank #3
Why Atlas Venture and Access Biotechnology matter
Atlas Venture and Access Biotechnology were new co-leads in the Series B. Atlas is a biotech-focused venture firm, while Access Biotechnology is the biopharma investment arm of Access Industries. Their representatives, Kevin Bitterman and Dan Becker, joined GRObio’s board in connection with the financing.
Their participation brings capital and board-level development experience, but investor enthusiasm is not independent proof of clinical or manufacturing success. The round’s strategic message is that two new specialist investors were willing to fund both a lead therapeutic and the underlying platform.
What the financing was expected to fund
- Clinical preparation for ProGly-Uricase. The company said the proceeds would help move the gout program toward the clinic and generate clinical efficacy data.
- Pipeline expansion. Capital was also intended for additional protein therapeutics, including applications beyond gout.
- Platform development. GRObio planned to extend its genomically recoded-organism capabilities and production workflow.
This is more than routine operating capital: it is a bet that one platform can produce several differentiated biologics while the lead program supplies a concrete test of the technology.
What was—and was not—established in July 2024
Established by the announcement
- The Series B financing closed at $60.3 million and was oversubscribed.
- Atlas Venture and Access Biotechnology co-led the round, with four existing investors participating.
- GRObio said it had generated preclinical evidence for its approach and demonstrated scalability of its platform.
- The stated objective was to advance ProGly-Uricase toward clinical development.
Not established by the announcement
- Human safety, efficacy or duration of uric-acid control.
- Successful prevention of anti-drug antibodies in patients.
- Regulatory clearance, approval probability or commercial launch timing.
- Company valuation, investor allocations, dilution, runway or manufacturing cost.
The release was company-issued and did not provide those financial or clinical details.
Key development risks
Platform breadth versus execution
A platform that can generate many engineered proteins could create several opportunities, but every candidate still needs its own pharmacology, toxicology, manufacturing and clinical evidence.
Novel chemistry versus regulatory complexity
Multiple non-standard amino acids may require extensive characterization of identity, purity, incorporation consistency, impurities, stability and process controls. These are development questions, not documented failures of GRObio.
Immunogenicity may not be solved by glycan engineering
Patients could still develop antibodies, or antibody reduction might not produce enough additional exposure to improve outcomes. The engineered protein could also lose activity, stability or manufacturability.
Capital and competition
Clinical programs commonly require additional financing beyond an early round. Delays in toxicology, manufacturing or regulatory review could increase cash needs, while competing gout treatments—including uricase strategies paired with immunomodulation—may evolve during development.
Development status as of August 18, 2026
GRObio’s current programs page continues to list ProGly-Uricase as a development program for severe, refractory gout and ProGly-AChR as a proposed therapy for myasthenia gravis: GRObio programs.
The available official material does not verify a current clinical-trial milestone for ProGly-Uricase. The most supportable description is therefore that the 2024 financing was intended to move the program into the clinic. It should not be described as proof that the drug entered successful human development, replaced existing uricase products or achieved clinical validation.
Bottom line
GRObio’s $60.3 million Series B was a vote of confidence in an ambitious protein-engineering platform and a specific problem in gout: antibody-mediated loss of uricase effectiveness. Its investment case depends on converting that preclinical rationale into reproducible manufacturing, lower immunogenicity and demonstrable patient benefit. Until clinical evidence is independently confirmed, the financing marks a planned transition toward validation—not validation itself.
Quick Recap
Product prices and availability are accurate as of the date/time indicated and are subject to change. Any price and availability information displayed on Amazon at the time of purchase will apply.
What’s actually slowing this PC down?
Pick the symptom - the matching free tool is one click away.
